[º¸°ÇŸÀÓÁî] ¸íÁöº´¿ø ´ºÈ£¶óÀÌÁðÇ׾Ͽ¬±¸¼Ò¿Í (ÁÖ)ĵ¼·Ó, (ÁÖ)MJ¼¿¹ÙÀÌ¿À´Â ¿À´Â 12¿ù 5ÀÏ ¿ÀÈÄ 2½Ã ¸íÁöº´¿ø ³óõȦ¿¡¼ ‘¸é¿ª¼¼Æ÷Ä¡·áÁ¦ °³¹ßÀÇ ÃÖ½ÅÁö°ß’(Current and Emerging methods for Immune Cell Therapy)À» ÁÖÁ¦·Î Á¶ÀÎÆ® ½ÉÆ÷Áö¾öÀ» °³ÃÖÇÑ´Ù.
³Ä¡¼º Áúȯ Ä¡·áÀÇ »õ·Î¿î ´ë¾ÈÀ¸·Î °ü½ÉÀ» ¸ðÀ¸°í ÀÖ´Â ¼¼Æ÷Ä¡·áÁ¦ ¿¬±¸ °³¹ßÀÇ »õ·Î¿î ÁöÆòÀ» ¿©´Â ȹ±âÀûÀÎ °è±â¸¦ ¸¶·ÃÇϱâ À§ÇØ °³ÃֵǴ À̹ø ½ÉÆ÷Áö¾öÀº ³»Àμº¼¼Æ÷Ä¡·áÁ¦¿Í À¯Àü°øÇÐÀû ¼¼Æ÷Ä¡·áÁ¦¿¡ ´ëÇÑ ±¹³»¿Ü ¼®ÇеéÀÇ ÃֽŠÁö°ßÀ» °øÀ¯ÇÏ°Ô µÈ´Ù.
°í·Á´ëÇб³ ÀÌ°æ¹Ì ±³¼ö°¡ ÁÂÀåÀ» ¸Ã°ÔµÇ´Â Á¦1¼¼¼ÇÀº ‘³»Àμº¼¼Æ÷Ä¡·áÁ¦ - Áõ°µÈ ETC Ä¡·á¸¦ À§ÇÑ ¹æ¹ýµé’(Endogenous cell therapy - Specialized methods of empowering ETC therapy)À» ÁÖÁ¦·Î ¸¶·ÃµÈ´Ù.
¹Ì±¹ Åػ罺´ëÇб³ MD¾Ø´õ½¼¾Ï¼¾ÅÍ Cassian Yee ±³¼ö°¡ ‘ÀÔ¾ç T¼¼Æ÷ Ä¡·á : Â÷¼¼´ë ¸é¿ª¼¼Æ÷Ä¡·á¸¦ À§ÇÑ »õ·Î¿î Ÿ°Ù’(Adoptive T Cell Therapy: New Targets for the Next Gemeration)À» ÁÖÁ¦·Î ÇÑ Æ¯º° °¿¬À» ÁøÇàÇÑ´Ù.
À̾î À¯Æ¿·º½º ÇÑÁ¤ÈÆ ºÎ»çÀåÀÌ ‘°íÇü¾Ï°ú Ç÷¾×¾Ï¿¡¼ À¯Æ¿·º½º 4-1BB T ¼¼Æ÷Ä¡·áÁ¦ÀÇ ÀÓ»óÀû Àû¿ë’(Clinical Implication of EUTILEX 4-1BB-based adoptive T cell therapy in Solid and Hematology Cancers)À» ÁÖÁ¦·Î ¹ßÇ¥ÇÑ´Ù.
‘À¯Àü°øÇÐÀû ¼¼Æ÷Ä¡·áÁ¦ – CAR T¸¦ À§ÇÑ Çõ½ÅÀûÀÎ À¯Àü°øÇйý’(Engineered Cell therapy - Innovative engineering methods of CAR T)À» ÁÖÁ¦·Î ÇÑ Á¦2¼¼¼Ç¿¡¼´Â ¿¥Á¦À̼¿¹ÙÀÌ¿ÀÀÇ À̹é½Â ºÎ»çÀåÀÌ ‘ÃéÀå¾ÏÀ» Æ÷ÇÔÇÑ °íÇü¾Ï ´ë»ó CAR T’(CAR-T Therapy against Solid Tumors Including Pancreatic Cancer)¿¡ ´ëÇØ ¼Ò°³ÇÑ´Ù.
¶Ç ÅøÁ¨ ±è¼®Áß ¿¬±¸¼ÒÀåÀÌ ‘T ¼¼Æ÷Ä¡·áÁ¦¸¦ À§ÇÑ À¯Àüü ÆíÁý¼úÀÇ Àû¿ë’(Application of genome editing in adoptive T cell therapies), ±¹¸³¾Ï¼¾ÅÍ ÇÑÃæ¿ë ¹Ú»ç°¡ ‘CAR T ÃÖÀûȸ¦ À§ÇÑ ÇÙ½É Á¶°Ç CAR Ä£¹Ðµµ’(CAR affinity as a key attribute for optimal CAR-T development)¸¦ ÁÖÁ¦·Î ¹ßÇ¥ÇÑ´Ù.
¹®ÀÇ ¹× »çÀüµî·ÏÀº 031)810-5024 jjw0904@mjh.or.kr